TWO PLATFORMS. ONE COMPANY
Distinct technologies.
Shared delivery expertise.
Each platform operates independently as a licensable technology with proprietary programs. Both benefit from Gyldenpharma’s core competence in precision intradermal and immune-targeted delivery — and each is available for strategic partnership.
AuNP Peptide Vaccine Platform
Ultra-small (3–5 nm) gold nanoparticles decorated with sugar moieties for self-adjuvanting activity, carrying multiple CD8 and CD4 T cell epitopes. Designed as a direct alternative to mRNA-LNP approaches — with superior stability, no cold chain, and no requirement for cellular translation.
Microneedle Patch Delivery Platform
Microneedle arrays for painless, reproducible intradermal delivery of small molecules, peptides, and biologics. Lead asset: zolmitriptan patch for chronic migraine, NDA-resubmission ready following FDA Type C and forthcoming Type D meeting alignment. Platform extendable to other partner compounds.
BUSINESS MODEL
A platform licensing company with proprietary programs.
Both platforms are available as licensable technology assets, providing partners with established IP, device, and regulatory packages. Gyldenpharma retains equity stakes in co-development programs.